Cargando…

Protective Role for LPA(3) in Cardiac Hypertrophy Induced by Myocardial Infarction but Not by Isoproterenol

Background: We previously reported that lysophosphatidic acid (LPA) promoted cardiomyocyte hypertrophy in vitro via one of its G protein-coupled receptor subtypes, LPA(3). In this study, we examined the role of LPA(3) in cardiac hypertrophy induced by isoproterenol (ISO) and myocardial infarction. M...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Lin, Fan, Guangpu, Wang, Fang, Liu, Si, Li, Tiewei, Cong, Xiangfeng, Chun, Jerold, Chen, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447740/
https://www.ncbi.nlm.nih.gov/pubmed/28611684
http://dx.doi.org/10.3389/fphys.2017.00356
_version_ 1783239406551826432
author Cai, Lin
Fan, Guangpu
Wang, Fang
Liu, Si
Li, Tiewei
Cong, Xiangfeng
Chun, Jerold
Chen, Xi
author_facet Cai, Lin
Fan, Guangpu
Wang, Fang
Liu, Si
Li, Tiewei
Cong, Xiangfeng
Chun, Jerold
Chen, Xi
author_sort Cai, Lin
collection PubMed
description Background: We previously reported that lysophosphatidic acid (LPA) promoted cardiomyocyte hypertrophy in vitro via one of its G protein-coupled receptor subtypes, LPA(3). In this study, we examined the role of LPA(3) in cardiac hypertrophy induced by isoproterenol (ISO) and myocardial infarction. Methods: In vitro, neonatal rat cardiomyocytes (NRCMs) were subjected to LPA(3) knocked-down, or pretreated with a β-adrenergic receptor (β-AR) antagonist (propranolol) before LPA/ISO treatment. Cardiomyocyte size and hypertrophic gene (ANP, BNP) mRNA levels were determined. In vivo, [Formula: see text] and wild-type mice were implanted subcutaneously with an osmotic mini-pump containing ISO or vehicle for 2 weeks; echocardiography was performed to determine the heart weight/body weight ratio, cardiomyocyte cross-sectional area, and level of ANP mRNA expression. [Formula: see text] and wild-type mice were subjected to permanent coronary artery ligation or sham surgery for 4 weeks; cardiac function, including the degree of hypertrophy and infarction size, was determined. Results: In vitro, we found that knocked-down LPA(3) in NRCMs did not attenuate ISO-induced hypertrophy, and propranolol was unable to abolish LPA-induced hypertrophy. In vivo, chronic ISO infusion caused cardiac hypertrophy in wild-type mice, while hypertrophic responses to ISO infusion were not attenuated in [Formula: see text] mice. However, in a myocardial infarction (MI) model, [Formula: see text] mice exhibited reduced cardiac hypertrophy compared to wild-type mice at 4 weeks post-MI, which was associated with reduced cardiac function and increased infarct size. Conclusions: Our data show that LPA(3) appears to play a protective role in myocardial hypertrophy post-MI, but does not appear to be involved in the hypertrophy that occurs in response to β-AR stimulation in vivo and in vitro. These results implicate LPA-LPA(3) lipid signaling in cardiac hypertrophy occurring after pathological insults like MI, which presents a new variable in β-AR-independent hypertrophy. Thus, modulation of LPA(3) signaling might represent a new strategy for preventing the stressed myocardium from ischemia injury.
format Online
Article
Text
id pubmed-5447740
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-54477402017-06-13 Protective Role for LPA(3) in Cardiac Hypertrophy Induced by Myocardial Infarction but Not by Isoproterenol Cai, Lin Fan, Guangpu Wang, Fang Liu, Si Li, Tiewei Cong, Xiangfeng Chun, Jerold Chen, Xi Front Physiol Physiology Background: We previously reported that lysophosphatidic acid (LPA) promoted cardiomyocyte hypertrophy in vitro via one of its G protein-coupled receptor subtypes, LPA(3). In this study, we examined the role of LPA(3) in cardiac hypertrophy induced by isoproterenol (ISO) and myocardial infarction. Methods: In vitro, neonatal rat cardiomyocytes (NRCMs) were subjected to LPA(3) knocked-down, or pretreated with a β-adrenergic receptor (β-AR) antagonist (propranolol) before LPA/ISO treatment. Cardiomyocyte size and hypertrophic gene (ANP, BNP) mRNA levels were determined. In vivo, [Formula: see text] and wild-type mice were implanted subcutaneously with an osmotic mini-pump containing ISO or vehicle for 2 weeks; echocardiography was performed to determine the heart weight/body weight ratio, cardiomyocyte cross-sectional area, and level of ANP mRNA expression. [Formula: see text] and wild-type mice were subjected to permanent coronary artery ligation or sham surgery for 4 weeks; cardiac function, including the degree of hypertrophy and infarction size, was determined. Results: In vitro, we found that knocked-down LPA(3) in NRCMs did not attenuate ISO-induced hypertrophy, and propranolol was unable to abolish LPA-induced hypertrophy. In vivo, chronic ISO infusion caused cardiac hypertrophy in wild-type mice, while hypertrophic responses to ISO infusion were not attenuated in [Formula: see text] mice. However, in a myocardial infarction (MI) model, [Formula: see text] mice exhibited reduced cardiac hypertrophy compared to wild-type mice at 4 weeks post-MI, which was associated with reduced cardiac function and increased infarct size. Conclusions: Our data show that LPA(3) appears to play a protective role in myocardial hypertrophy post-MI, but does not appear to be involved in the hypertrophy that occurs in response to β-AR stimulation in vivo and in vitro. These results implicate LPA-LPA(3) lipid signaling in cardiac hypertrophy occurring after pathological insults like MI, which presents a new variable in β-AR-independent hypertrophy. Thus, modulation of LPA(3) signaling might represent a new strategy for preventing the stressed myocardium from ischemia injury. Frontiers Media S.A. 2017-05-30 /pmc/articles/PMC5447740/ /pubmed/28611684 http://dx.doi.org/10.3389/fphys.2017.00356 Text en Copyright © 2017 Cai, Fan, Wang, Liu, Li, Cong, Chun and Chen. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Physiology
Cai, Lin
Fan, Guangpu
Wang, Fang
Liu, Si
Li, Tiewei
Cong, Xiangfeng
Chun, Jerold
Chen, Xi
Protective Role for LPA(3) in Cardiac Hypertrophy Induced by Myocardial Infarction but Not by Isoproterenol
title Protective Role for LPA(3) in Cardiac Hypertrophy Induced by Myocardial Infarction but Not by Isoproterenol
title_full Protective Role for LPA(3) in Cardiac Hypertrophy Induced by Myocardial Infarction but Not by Isoproterenol
title_fullStr Protective Role for LPA(3) in Cardiac Hypertrophy Induced by Myocardial Infarction but Not by Isoproterenol
title_full_unstemmed Protective Role for LPA(3) in Cardiac Hypertrophy Induced by Myocardial Infarction but Not by Isoproterenol
title_short Protective Role for LPA(3) in Cardiac Hypertrophy Induced by Myocardial Infarction but Not by Isoproterenol
title_sort protective role for lpa(3) in cardiac hypertrophy induced by myocardial infarction but not by isoproterenol
topic Physiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5447740/
https://www.ncbi.nlm.nih.gov/pubmed/28611684
http://dx.doi.org/10.3389/fphys.2017.00356
work_keys_str_mv AT cailin protectiveroleforlpa3incardiachypertrophyinducedbymyocardialinfarctionbutnotbyisoproterenol
AT fanguangpu protectiveroleforlpa3incardiachypertrophyinducedbymyocardialinfarctionbutnotbyisoproterenol
AT wangfang protectiveroleforlpa3incardiachypertrophyinducedbymyocardialinfarctionbutnotbyisoproterenol
AT liusi protectiveroleforlpa3incardiachypertrophyinducedbymyocardialinfarctionbutnotbyisoproterenol
AT litiewei protectiveroleforlpa3incardiachypertrophyinducedbymyocardialinfarctionbutnotbyisoproterenol
AT congxiangfeng protectiveroleforlpa3incardiachypertrophyinducedbymyocardialinfarctionbutnotbyisoproterenol
AT chunjerold protectiveroleforlpa3incardiachypertrophyinducedbymyocardialinfarctionbutnotbyisoproterenol
AT chenxi protectiveroleforlpa3incardiachypertrophyinducedbymyocardialinfarctionbutnotbyisoproterenol